<DOC>
	<DOC>NCT01686607</DOC>
	<brief_summary>This multicenter observational cohort study proposes to establish the risks of short and long-term outcomes in users of parenteral micafungin and in users of other parenteral antifungal agents from 2005 through 2012 with follow-up until 2017.</brief_summary>
	<brief_title>Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents</brief_title>
	<detailed_description>All eligible patients treated with a parenteral antifungal agent at any time during the years 2005-2012 in each of the participating hospitals, will be included in the study.</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>hospitalized and treated with parenteral antifungal medication first time treatment of the patient with parenteral antifungal in the medical center was anytime from 2005 through 2012 prior diagnosis of hepatocellular carcinoma had received parenteral antifungal therapy during the 6 months prior to index hospitalization</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatic toxicity</keyword>
	<keyword>Renal toxicity</keyword>
	<keyword>Micafungin</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Antifungals (parenteral)</keyword>
</DOC>